We use cookies to measure traffic and show relevant ads. By clicking Accept you agree to our use of analytics and advertising cookies.
FDA approved pivekimab sunirin (Decnupaz) for BPDCN with complete remission of 69.7%. Analysis of efficacy, risks, price, and prospects in AML. Read more.
